Quercetin
  n 0.1 0.3 1 3 10 30 100 μM
  Control   A   10   1.6 ± 0.94   8.0 ± 1.71)   23.4 ± 3.22) 33.9 ± 2.72) 55.5 ± 3.23)   69.8 ± 3.43)   99.6 ± 3.03)
  Endothelium-denuded   6   1.8 ± 0.55   3.8 ± 1.6b)   8.5 ± 1.9b)   13.0 ± 2.6b)   30.8 ± 4.9)b)   44.2 ± 4.2b)   77.9 ± 2.4b)
  L-NAME 100µM   8   1.3 ± 0.9   3.2 ± 1.8   19.2 ± 3.4   31.0 ± 2.8   51.2 ± 2.0   62.3 ± 4.7   86.0 ± 7.0a)
  B                
  L-NAME+
Indomethacin(100µM)
  8   1.9 ± 0.75   4.1 ± 1.3   19.0 ± 7.3   31.2 ± 6.3   52.5 ± 7.8   63.2 ± 6.9   82.0 ± 2.2
  +TEA(100µM)   6   1.3 ± 0.80   7.5 ± 2.9   20.2 ± 5.7   32.0 ± 3.0   52.5 ± 2.6   67.8 ± 2.4   82.0 ± 2.4
  +glycyrrhetinicacids   9   2.2 ± 1.3   5.5 ± 2.8   11.5 ± 5.0   20.5 ± 5.3   35.0 ± 6.0a)   51.1 ±4.3a)   63.3 ± 5.5b)
Values (%) represent mean ± S.E.M. 1) and a): p<0.05, 2) and b) :p<0.01, 3): p<0.001. Symbols of 1), 2), and 3) mean significant differences in comparison between effects of quercetin itself at each concentration and the maximal contraction induced by NE.A) The symbol of a), b) indicate significant difference as compared with control (quercetin alone) values. B) The symbol of a), b) indicate significant difference as compared with L-NAME and indomethacin.
Table 4: Modulation of endothelium-dependent relaxation induced by quercetin in rat mesenteric artery.